Wordt geladen...
Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
INTRODUCTION: EGFR exon 20 insertion mutations account for 10% of all EGFR mutations and are mostly insensitive to approved EGFR tyrosine kinase inhibitors (EGFR TKIs). Novel EGFR TKIs have been developed or repurposed for these mutants. A limited number of preclinical studies have detailed these EG...
Bewaard in:
| Gepubliceerd in: | JTO Clin Res Rep |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Elsevier
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7959160/ https://ncbi.nlm.nih.gov/pubmed/33728415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtocrr.2020.100105 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|